A small cap company’s upcoming Phase 2 Alzheimer's drug data presentation this week

TTHI is going to be presenting data on their Alzheimer's disease drug (ELND-005) at the Alzheimer's conference this week. If the trials data is positive, it brings the company one step closer to the approval of their breakthrough treatment for Alzheimer's disease. To find out about the drug, how the drug works, who are the other players developing drugs in this area and how TTHI's drug compares with the rest, read a FREE report of the upcoming trials data at: http://www.newbiomedicine.com